Foley S J, Soloman L Z, Wedderburn A W, Kashif K M, Summerton D, Basketter V, Holmes S A
Department of Urology, St. Mary's Hospital, Portsmouth, United Kingdom.
J Urol. 2000 Feb;163(2):496-8.
We prospectively studied the effect of finasteride on chronic hematuria associated with benign prostatic hyperplasia.
We prospectively evaluated 57 patients with chronic intermittent hematuria who were randomized to a finasteride treated or a control arm.
In the untreated control group hematuria recurred in 17 patients (63%) within a year but in only 4 (14%) in the finasteride group, which was a statistically significant difference (p <0.05). Surgery was required for bleeding in 7 controls (26%), while no patient on finasteride required surgery.
Hematuria secondary to prostatic bleeding may be significant if not treated. Finasteride appears to be effective for suppressing hematuria caused by benign prostatic hyperplasia and should be considered as treatment.
我们前瞻性地研究了非那雄胺对与良性前列腺增生相关的慢性血尿的影响。
我们前瞻性地评估了57例慢性间歇性血尿患者,他们被随机分为非那雄胺治疗组或对照组。
在未治疗的对照组中,17例患者(63%)在一年内血尿复发,但在非那雄胺组中只有4例(14%),这是一个具有统计学意义的差异(p<0.05)。7例对照组患者(26%)因出血需要手术,而服用非那雄胺的患者均无需手术。
前列腺出血继发的血尿若不治疗可能较为严重。非那雄胺似乎对抑制良性前列腺增生引起的血尿有效,应考虑作为一种治疗方法。